Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference

MT Newswires Live

12/03

Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.

In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.

Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.

Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588706497"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588706497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588706497?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588706497","market":"sg","top_or_hot":-1,"title":"Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference","media":"MT Newswires Live","content":"<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-03 06:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588706497","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588706497","pubTimestamp":1764716292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen  and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BIIB":"渤健公司","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Biogen和卫材在2025年阿尔茨海默病临床试验会议上展示新的LEQEMBI生物标志物数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}